COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib : A Case Report
Copyright © 2022, Shimada et al..
Remdesivir, dexamethasone, and baricitinib have recently been used to treat patients with coronavirus disease 2019 (COVID-19) and respiratory failure. However, the adverse effects of combination therapy have not been fully explored. A 64-year-old man was diagnosed with COVID-19 and was treated with remdesivir, dexamethasone, and baricitinib. His respiratory condition worsened on day 17, and in the following days, he was diagnosed with pneumomediastinum and COVID-19-associated pulmonary aspergillosis (CAPA). His condition improved with a reduction in the corticosteroid regime and antifungal treatment. This is the first case of pulmonary aspergillosis in a patient with COVID-19 that was treated with remdesivir, dexamethasone, and baricitinib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cureus - 14(2022), 4 vom: 22. Apr., Seite e23755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shimada, Ayako [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Baricitinib |
|---|
| Anmerkungen: |
Date Revised 16.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.23755 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340470925 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340470925 | ||
| 003 | DE-627 | ||
| 005 | 20231226005329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.23755 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340470925 | ||
| 035 | |a (NLM)35518522 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shimada, Ayako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib |b A Case Report |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022, Shimada et al. | ||
| 520 | |a Remdesivir, dexamethasone, and baricitinib have recently been used to treat patients with coronavirus disease 2019 (COVID-19) and respiratory failure. However, the adverse effects of combination therapy have not been fully explored. A 64-year-old man was diagnosed with COVID-19 and was treated with remdesivir, dexamethasone, and baricitinib. His respiratory condition worsened on day 17, and in the following days, he was diagnosed with pneumomediastinum and COVID-19-associated pulmonary aspergillosis (CAPA). His condition improved with a reduction in the corticosteroid regime and antifungal treatment. This is the first case of pulmonary aspergillosis in a patient with COVID-19 that was treated with remdesivir, dexamethasone, and baricitinib | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a baricitinib | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a jak inhibitor | |
| 650 | 4 | |a pulmonary aspergillosis | |
| 650 | 4 | |a respiratory failure | |
| 700 | 1 | |a Ohnaka, Shinnosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Kosumi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Masanao |e verfasserin |4 aut | |
| 700 | 1 | |a Nagai, Atsushi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 14(2022), 4 vom: 22. Apr., Seite e23755 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:4 |g day:22 |g month:04 |g pages:e23755 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.23755 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 4 |b 22 |c 04 |h e23755 | ||